Alle verbonden artikelen

Percutaneous endoscopic jejunostomy in patients with gastroparesis following lung transplantation: feasibility and clinical outcome.

Auteurs : Toussaint E, Van Gossum A, Ballarin A, Le Moine O, Estenne M, Knoop C, Devière J, Arvanitakis M
Jaar : 2012
Journal : Endoscopy
Volume : 44(8)
Pagina's : 772-5

Clinical development of new formulations of cytotoxics in solid tumors.

Auteurs : Azim HA, Awada A
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pagina's : 325-31

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Auteurs : Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, van de Vijver M, Viale G, Loi S, Reis-Filho JS
Jaar : 2012
Journal : Ann Oncol
Volume : 23
Pagina's : 2997-3006

Význam biomarkerù v klinické onkologii

Auteurs : Klastersky J
Jaar : 2012
Journal : lekarsky Sbornik
Volume : sup1
Pagina's : 14-17

Esophageal self-expanding metallic stent (SEMS) migration: it's a topsy-turvy world.

Auteurs : Toussaint E, Zalcman M, Devière J, Le Moine O, Arvanitakis M
Jaar : 2012
Journal : Endoscopy
Volume : 44 Suppl 2
Pagina's : E352-3

Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology.

Auteurs : Awada A, Vandone AM, Aftimos P
Jaar : 2012
Journal : Curr Opin Oncol
Volume : 24(3)
Pagina's : 297-304

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.

Auteurs : Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, de Azambuja E, Piccart-Gebhart M
Jaar : 2012
Journal : Ann Oncol
Volume : 23(4)
Pagina's : 853-859

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.

Auteurs : Van Laethem JL, Verslype C, Iovanna JL, Michl P, Conroy T, Louvet C, Hammel P, Mitry E, Ducreux M, Maraculla T, Uhl W, Van Tienhoven G, Bachet JB, Maréchal R, Hendlisz A, Bali M, Demetter P, Ulrich F, Aust D, Luttges J, Peeters M, Mauer M, Roth A, Neoptolemos JP, Lutz M
Jaar : 2012
Journal : Ann Oncol
Volume : 23
Pagina's : 570-576

Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer - Authors' reply.

Auteurs : Baselga J, de Azambuja E, Bradbury I, Gelber R
Jaar : 2012
Journal : Lancet
Volume : 379 (9833)
Pagina's : 2238

Minimal residual disease and circulating tumor cells in breast cancer: open questions for research.

Auteurs : Ignatiadis M, Sotiriou C, Pantel K
Jaar : 2012
Journal : Recent Results Cancer Res.
Volume : 195
Pagina's : 3-9

New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

Auteurs : Awada A, Bozovic-Spasojevic I, Chow L
Jaar : 2012
Journal : Cancer Treat Rev
Volume : 38(5)
Pagina's : 494-504

Clinical trial design in head and neck cancer: from past experiences to future perspectives.

Auteurs : de Castro G Jr, Henrique dos Anjos C, Lalami Y, Awada A
Jaar : 2012
Journal : Clinical Investigation
Volume : 2(5)
Pagina's : 473-481

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

Auteurs : Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H, Linderholm BK, Martin M, Penault-Llorca F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S, Viale G
Jaar : 2012
Journal : Breast
Volume : 21(1)
Pagina's : 20-6

Understanding the biology of triple-negative breast cancer.

Auteurs : Criscitiello C, Azim HA, Schouten PC, Linn SC, Sotiriou C
Jaar : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pagina's : vi13-vi18

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Auteurs : Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart-Gebhart M, Harbeck N
Jaar : 2012
Journal : Breast Cancer Res. Treat.
Volume : 134(3)
Pagina's : 1149-59

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

Auteurs : Berghmans T, Remmelink M, Awada A
Jaar : 2012
Journal : Lung Cancer : Targets and Therapy
Volume : 3
Pagina's : 91-99

Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.

Auteurs : Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Viganò L, Huang X, Verkh L, Kern KA, Giorgetti C, Gianni L
Jaar : 2012
Journal : Breast
Volume : 21(4)
Pagina's : 507-13

Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.

Auteurs : Azim H, Azim HA
Jaar : 2012
Journal : Future Oncol
Volume : 8(2)
Pagina's : 135-44

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

Auteurs : Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart-Gebhart M
Jaar : 2012
Journal : Lancet Oncol
Volume : 13(6)
Pagina's : e240-8

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

Auteurs : Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, Gómez JM, Bonichon F, Leenhardt L, Soufflet C, Licour M, Schlumberger MJ
Jaar : 2012
Journal : Lancet Oncol
Volume : 13(9)
Pagina's : 897-905